Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines.
The activity of carboplatin (CBDCA) was tested in 21 consecutive patients with advanced colorectal cancer that had progressed during fluoropyrimidine therapy. CBDCA was chosen in view of the favourable results obtained in previous phase II studies. We were unable to find any activity of the agent which was given every 21 days at a dose of 400 mg/m2. The main toxicity was haematological. CBDCA is not recommended in pretreated patients with colorectal cancer.
Nolè
F
F
Divisione di Oncologia Medica B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Biganzoli
L
L
Buzzoni
R
R
Bajetta
E
E
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy*; D016879:Salvage Therapy
D016190:Carboplatin; D005472:Fluorouracil